SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy전신 경화증 환자의 SARS-CoV-2 백신: 질병 하위 유형 및 치료의 영향Clinical Trial Published on 2022-06-282022-09-12 Journal: Rheumatology (Oxford, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] affected affecting anti-SARS-CoV-2 Antibody Response baseline comparable Control controls CoronaVac disease dose Factor first dose Follow-up Frequency immunogenicity immunosuppressive inactivated individual Interstitial lung disease majority median age MMF moderate monotherapy Most patient Multiple mycophenolate neutralizing antibody Participants Patient Prospective Study regression analysis respiratory safety profile SARS-CoV-2 SARS-CoV-2 vaccine Seroconversion Side-effect subgroup of patients Systemic sclerosis therapy Trial vaccination Vaccine vaccine response were assessed [DOI] 10.1093/rheumatology/keab886 PMC 바로가기 [Article Type] Clinical Trial
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial무작위 2상 시험에서 BBIBP-CorV 수용자에서 하이브리드형 백신 부스터의 안전성 및 면역원성Clinical Trial Published on 2022-06-272022-09-11 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, 치료법, [키워드] 1:1 Administered Adverse reaction Adverse reactions age Antigen antigens BBIBP-CorV boost booster booster dose conducted dose double-blind elicited evaluate GMT greater group healthy Heterologous homologous IgG antibodies IgG antibody immunogenic immunogenicity incidence Neutralizing and IgG antibodies neutralizing antibody omicron Omicron variant participant Phase 2 phase 2 trial Randomized receive recipient recombinant COVID-19 vaccine regimens Safe Safety safety profile SARS-CoV-2 SARS-CoV-2 strain significantly higher three groups United Arab Emirate United Arab Emirates Vaccine variant variants of concern VOCs [DOI] 10.1038/s41467-022-31379-0 PMC 바로가기 [Article Type] Clinical Trial
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial건강한 어린이에서 비활성화된 COVID-19 백신 WIBP-CorV의 안전성 및 면역원성: 무작위, 이중 맹검, 대조, 1/2상 시험의 중간 분석Clinical Trial Published on 2022-06-242022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] adverse events Adverse reaction Adverse reactions age alum Antibody Response assigned children China clinical trial Cohort cohorts conducted Controlled COVID-19 COVID-19 vaccine detectable dose dose-escalation double-blind effective vaccine Effective vaccines elicited Escalation Fever followed by geometric mean geometric mean titer geometric mean titers grade 3 groups healthy children Humoral response immunogenicity inactivated Inactivated vaccine injection injection site pain Interim Intramuscular injection Mild neutralizing antibody participant phase Phase 1 phase 1 trial Phase 2 phase 2 trial Placebo placebo-controlled Randomized Randomly ranged Registered robust Safe Safety safety profile SARS-CoV-2 significantly higher tested three group three groups vaccination Vaccine [DOI] 10.3389/fimmu.2022.898151 PMC 바로가기 [Article Type] Clinical Trial
A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes Research Published on 2022-06-242022-10-05 Journal: Nature Communications [Category] 임상, 진단, [키워드] agonist Analysis baseline blood glucose China Chinese patient clinically Cohort cohorts conducted decreased appetite develop diarrhoea effective Efficacy effort eight enrolled evaluate Glucose Haemoglobin investigator involved MOST nausea nine obesity Open-label outcome Patient patients Placebo placebo-controlled plasma randomised randomised controlled trial receive receiving receptor reduced reductions in safety profile secondary subcutaneously T2D Tolerability Tolerance treat Treatment treatment-emergent adverse event type 2 diabete [DOI] 10.1038/s41467-022-31328-x [Article Type] Research
Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective studyObservational Study Published on 2022-06-212022-10-05 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 임상, [키워드] 95% CI Administered Adverse adverse event AESI AESIs all-cause mortality Analysis anaphylaxis authority Bell BNT162b2 Characteristics cohort study comparable CoronaVac coronavirus disease country COVID-19 COVID-19 vaccine COVID-19 vaccines cumulative disorder dose electronic medical record event Evidence first dose Follow-up group help Hong Kong inactivated Inactivated vaccine incidence incidence rate include individual individuals limitation Mortality mRNA mRNA vaccines mRNA-based vaccine no significant difference observation period of BNT162b2 Poisson regression models population-based cohort populations rate ratio recipient recipients recorded reduce reported residual confounding retrospective Retrospective study Safety safety profile SARS-CoV-2 vaccine SARS-CoV-2 vaccines second dose significantly higher Surveillance the vaccine Thromboembolism vaccinated individual vaccination Vaccine Vaccine hesitancy Weighting were excluded [DOI] 10.1371/journal.pmed.1004018 PMC 바로가기 [Article Type] Observational Study
Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial남아프리카의 Sisonke 연구에서 의료 종사자를 대상으로 한 단회 용량 Ad26.COV2.S 백신의 안전성 평가: 3b상 시행 시험Clinical Trial Published on 2022-06-212022-09-12 Journal: PLoS Medicine [Category] MERS, 임상, 진단, [키워드] 48 hour Ad26.COV2.S vaccine adverse event AEs African age body ache breakthrough infections categories clinical clinical trials collected COVID-19 COVID-19 infection death demonstrated Effectiveness eligible evaluated expected Fever Final first vaccination Frequency HCW HCWs headache healthcare healthcare worker hospitalisations Immune system disorder implementation Implementation study IMPROVE incidence rate increasing age Infection injection site pain janssen men morbidity MOST National nervous system disorder occurred Open-label Pan participant Participants Phase 3 trials reactogenicity reactogenicity event Registered registry reported SAE SAEs safety evaluation safety profile serious AE single-arm design South South Africa Support Symptoms syndrome System thrombosis Trial triggered vaccination Vaccine [DOI] 10.1371/journal.pmed.1004024 PMC 바로가기 [Article Type] Clinical Trial
A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) InhibitorsSARS-CoV-2 주요 프로테아제(3CLpro) 억제제 식별을 위한 약물 용도 변경 연구Article Published on 2022-06-092022-09-11 Journal: International Journal of Molecular Sciences [Category] Coronavirus, COVID19(2023년), SARS, 신약개발, 치료제, [키워드] 3CL 3CLpro acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered Antiviral antiviral activity artificial artificial intelligence caused Cell Combination Compound compounds coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 cynarine cytotoxicity docking drug Drug repurposing eravacycline FRET in silico in vitro infected with SARS-CoV-2 inhibitory activity inhibitory compounds intelligence MPro outbreak phase prexasertib protease repurposing safety profile SARS-CoV-2 SARS-CoV-2 3CL protease SARS-CoV-2 main protease selected severe acute respiratory syndrome Coronavirus tested the disease Treatment trials Vaccine VeroE6 cell VeroE6 cells were used [DOI] 10.3390/ijms23126468 PMC 바로가기 [Article Type] Article
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trialBBIBP-CorV로 프라이밍한 후 이종 부스터로서의 NVSI-06-07의 면역원성과 안전성: 2상 시험Clinical Trial Published on 2022-06-062022-09-11 Journal: Signal Transduction and Targeted Therapy [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 1:1 Adverse reactions Alpha assigned BBIBP-CorV Beta boost booster booster vaccination conducted control groups coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine Delta double-blinded elicited followed by geometric mean geometric mean titer GMT GMTs group groups healthy Heterologous heterologous prime-boost homologous immunogenic immunogenicity immunogenicity assays inactivated increase Increases indicated individual Mild moderate Neutralizing neutralizing antibody omicron Omicron variant Participants Phase 2 phase 2 trial priming prototype randomised Randomly receive recipient Recombinant protein Safe safety profile SARS-CoV-2 SARS-CoV-2 variant significantly higher systemic adverse reaction three groups vaccination Vaccine variant VOCs [DOI] 10.1038/s41392-022-00984-2 PMC 바로가기 [Article Type] Clinical Trial
Acceptance and willingness to pay under the different COVID-19 vaccines: A contingent valuation methodResearch article Published on 2022-06-012022-10-05 Journal: Research in social & administrative pharmacy : RSA [Category] 변종, [키워드] acceptance addition Affect affecting approach Characteristics collected conducted Contingent valuation method COVID-19 COVID-19 infection COVID-19 vaccination COVID-19 vaccine cross-sectional survey develop Effectiveness expressed Factor Government highest hypothetical identify IMPROVE knowledge Linear regression Logistic regression Multiple multivariate objective Perceived risk predictor question Result safety profile the vaccine understanding vaccination Vaccine Vaccines was performed was used Willingness to pay [DOI] 10.1016/j.sapharm.2022.06.001 [Article Type] Research article
Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19COVID-19에 대한 비강내 예방으로서 광범위한 변이 활성을 갖는 계란 유래 항-SARS-CoV-2 면역글로불린 Y(IgY)Clinical Trial Published on 2022-06-012022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 2019 novel coronavirus 2019-nCoV activity Administered Against Alpha anti-SARS-CoV-2 Antiviral approval approvals B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta binding capture chicken immunoglobulin clinical clinical trial clinical trial body Clinical use contagiousness Convalescent patients COVID-19 cross-reactivity Delta demonstrated develop Diseases distribution double-blind effective Emergency use authorization enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay Evidence evidence of greater healthy human tissue human tissues IgY Immunity immunized Immunoglobulin immunoglobulin Y index Infectious diseases intranasal intranasally multiple dose multiple doses nasal drop nasal drops nasal mucosa neutralization titer no evidence of Novel coronavirus omicron Phase 1 phase 1 study Placebo placebo-controlled Prevalence Prophylaxis raised Randomized RATs RBD Receptor-binding domain reduce reduced risk Safe safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 strain SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 viral sensitivity sera Spike protein the receptor-binding domain the SARS-CoV-2 Tolerability Transmission Trial Vaccine Vaccine hesitancy variants variants of concern variety Viral virus [DOI] 10.3389/fimmu.2022.899617 PMC 바로가기 [Article Type] Clinical Trial